Function Health nets $450M from General Catalyst to prove preventive care is cheaper than waiting to get sick

Function Health has secured $450 million in growth financing from General Catalyst's Customer Value Fund, marking a significant capital injection into the preventive healthcare technology sector. The funding is structured as non-dilutive capital, preserving the company's ownership structure while providing substantial resources for expansion. This financing underscores investor confidence in the preventive care model and Function's execution within a market increasingly focused on early disease detection and cost reduction.

The Austin-based platform has achieved substantial operational scale, having administered over 100 million lab tests to approximately 500,000 U.S. members. Function's business model centers on providing personalized health screenings through a comprehensive 160-panel laboratory offering paired with convenient at-home phlebotomy services. The company has strategically expanded its service ecosystem through acquisitions and integrations, including Getlabs' at-home blood draw capabilities, Ezra's full-body MRI imaging services, and SuppCo's supplement intelligence platform, creating a vertically integrated health service provider.

Central to Function's growth strategy is the development of Medical Intelligence Labs, an AI-powered diagnostic analysis tool designed to convert raw health data into actionable, personalized recommendations. The platform integrates with multiple major AI assistants—ChatGPT Health, Claude, Copilot, and Perplexity—positioning Function at the intersection of diagnostic testing and artificial intelligence-driven health guidance. This approach leverages diagnostic data collection as a mechanism to build proprietary health insights and establish ongoing engagement with users.

Function plans to deploy the General Catalyst capital toward accelerated customer acquisition domestically while pursuing geographic expansion into Canada, Europe, and Asia-Pacific markets. According to sources, the company is leveraging General Catalyst's expertise in customer acquisition models to improve unit economics and market penetration velocity. CEO Jonathan Swerdlin has articulated the strategic vision of making preventive health diagnostics accessible to billions of individuals globally, positioning Function within the broader healthcare transformation toward value-based, prevention-centric care models rather than reactive treatment-focused approaches.